Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

Phase 3

Completed

Conditions: Acute Ankle Sprain

Interventions: Drug: Placebo
Drug: SST-0225 Topical Ibuprofen Cream

Registration Number: NCT01874626

Lead Sponsor: Strategic Science & Technologies, LLC

Brief Summary: This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 305

Inclusion Criteria

Male and female subjects ≥16 years of age
Grade I or II acute ankle sprain injury within 24 hours prior to first use of investigational product.
1. Grade I: when the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior drawer test is negative
2. Grade II: moderate sprain, which usually results in partial tears of the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling
At screening (Visit 1), subject reported pain intensity score upon movement of ≥ 5 on a 0-10 Numerical Rating Scale (NRS)
Subject's Assessment of Normal Function/Activity (must be > 2) at screening
Able to comply with the visit schedule
Able to apply the investigational product as directed
Females of childbearing potential must be willing to use an approved method of birth control during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.
1. Effective methods of birth control: e.g. prescription oral, vaginal or transdermal contraceptives; contraceptive implants or injections; intrauterine device; diaphragm/cervical cap/condom with spermicide
2. Other acceptable methods of birth control include: Postmenopausal or amenorrhea for one year, Surgically sterile (hysterectomy, tubal ligation, or oopherectomy), Premenarcheal
Able to speak, read and comprehend English and record requested measurements as outlined in the protocol
Subject must be able to read, understand, sign and date the informed consent document (and the subject assent form, if necessary) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial

Exclusion Criteria

Subjects meeting any of the following criteria will not be entered in the study:

Similar injury of the same joint within the last 6 months
Clinical evidence of complete rupture of ankle ligaments (third degree sprain)
Requirements for bed rest, hospitalization, or surgical intervention for the ankle injury
Evidence of fractures or non-removable full cast of any type
Presence of bilateral occurrence of ankle injury or ipsilateral ankle and/or knee injury
Open wound or infection at site of injury
Significant Skin irritation at the application site;
Use of longer half life NSAID within 12 hours prior to study entry (Appendix 4)
Does not agree to use only supplied investigational product and rescue medication for analgesia during the seven days of the study or expects to require analgesics during the study for pain other than for ankle pain
Presence or history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the excipients in the investigational product (L-Arginine hydrochloride, Glyceryl Stearate, Cetyl Alcohol, Squalane, Xanthan Gum, Isopropyl Myristate, Oleic Acid, Propylene Glycol, Polysorbate -20)
Medical conditions including: peptic ulcer disease; clinically important gastrointestinal, renal, or hepatic disease within the past 6 months; clinically significant cardiovascular disease not stable for the past 6 months; uncontrolled hypertension as indicated by systolic blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater than or equal to 100 mm Hg; coagulation disorders or hematologic disease; history of seizures; or known, significant, pre-existing conditions that would affect the interpretation of any potential adverse reactions to the study medication
Known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months
Females who are pregnant or lactating.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo topical formulation (Reference product)
Active	SST-0225 Topical Ibuprofen Cream	SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen

Primary Outcome Measures

Name	Time	Method
24 Hour SPID	24 Hours	Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1

Secondary Outcome Measures

Name	Time	Method
Use of rescue medication including time to first use	7 days	• Use of rescue medication including time to first use (first 12 hours), proportion of subjects using rescue and amount of rescue medication used.
Mean change from baseline in pain scores on movement	First 24 hours	• Mean change from baseline in pain scores on movement at hours 6, 8, 10, 12, 20 and 24 hours over the first 24 hours.
Subject's global evaluation of investigational product	7 days	• Subject's global evaluation of investigational product evaluated at Days 2, 4 and 7 (or End-of-Study) based on a 5 point scale.
Change from baseline in pain scores on movement	7 days	• Change from baseline in pain scores on movement at time of each dose on Days 2-7.
Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief	First 4 hours	• Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief over the four-hour in-office phase of the study.
Mean change from baseline in subject reported pain intensity	First 4 hours	• Mean change from baseline in subject reported pain intensity (at rest and on movement) and pain relief (on movement only) as assessed at 15 minutes, 30 minutes, and hourly up to 4 hours following the first application on Day 1.
Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity	First 24 hours	• Percent of subjects with \> 15%, \> 30% and \> 50% reductions in pain intensity from baseline at 24 hours.
Number and percent of patients with systemic and local (skin) self-reported adverse events	7 days	Number and percent of patients with systemic and local (skin) self-reported adverse events.